Company / Cash & Equivalents
Adaptimmune Therapeutics PLC Cash & Equivalents History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$91.1M
FY2024
5-year range
$56.9M / $149.9M
FY2020-FY2024
Trend
-36.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $50M in FY2019 to $159M in FY2016.
Based on SEC 10-K filings.
$91M in FY2024 with a 5-year CAGR of +12.6%.
Declined from $108M to $91M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -15.3%
- 5-Year CAGR
- +12.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +12.6%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 36.7% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $91.1M | -36.7% |
| FY2023 | $144.0M | +33.3% |
| FY2022 | $108.0M | -28.0% |
| FY2021 | $149.9M | +163.6% |
| FY2020 | $56.9M | +12.8% |
| FY2019 | $50.4M | -26.3% |
| FY2018 | $68.4M | -18.6% |
| FY2017 | $84.0M | -47.1% |
| FY2016 | $158.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026